References

BIOFREEDOM™
POLYMER-FREE DRUG-COATED CORONARY STENT SYSTEM

Powered by BA9™ BIOLIMUS A9™

Journal Papers [1-11]

1. **Gaspardone A.** Angiographic and clinical performance of polymer-free biolimus-eluting stent in patients with ST-segment elevation acute myocardial infarction in a metropolitan public hospital: The BESAMI MUCHO study http://onlinelibrary.wiley.com/doi/10.1002/ccd.27206/abstract

2. **Morice M-C.** Drug-coated versus bare-metal stents for elderly patients: A predefined sub-study of the LEADERS FREE trial. Impact Factor 4.638 http://www.internationaljournalofcardiology.com/article/S0167-5273(17)30829-X/abstract

3. **Garot P. et al.** Two-Year Outcomes of High Bleeding Risk Patients after Polymer-Free Drug-Coated Stents. DOI: 10.1016/j.jacc.2016.10.009. Impact Factor 17.759 *http://www.onlinejacc.org/content/early/2016/11/23/j.jacc.2016.10.009*

4. **Costa R. et al.** Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions. http://dx.doi.org/10.1016/j.jcin.2015.09.008 Impact Factor 7.630 *http://www.interventions.onlinejacc.org/content/9/1/51*

5. **Kinnaird T. et al.** Early Clinical Experience with a Polymer-Free Biolimus A9 Drug-Coated Stent in DES-Type Patients Who Are Poor Candidates for Prolonged Dual Anti-Platelet Therapy. *http://dx.doi.org/10.1371/journal.pone.0157812. Impact Factor 3.057 http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0157812*

6. **Naber CK. et.al.** Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study. DOI: http://dx.doi.org/10.1093/eurheartj/ehw203. Impact Factor 15.203 *http://eurheartj.oxfordjournals.org/content/early/2016/05/13/eurheartj.ehw203*

Journal Papers [5-11]

7. **Urban P. et al.** Polymer-free Drug-Coated Stents in Patients at High Bleeding Risk. NEJM 2015; published ahead of print October 14; DOI:10.1056/ NEJMoa1503943. Impact Factor 55.873
http://www.nejm.org/doi/full/10.1056/NEJMoa1503943?af=R&rss=currentIssuE

8. **Costa R. et al.** Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions. JACC Interv 2015; in press. Impact Factor 7.345
http://www.sciencedirect.com/science/article/pii/S1936879815013928

9. **Urban P. et al.** Rationale and design of the LEADERS FREE trial: A randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy.
Am Heart J 2013;165:704-709. Impact Factor 3.28
http://www.ahjonline.com/article/S0002-8703(13)00057-4/pdf

10. **Waksman, R., et al.** In vivo comparison of a polymer-free Biolimus A9-eluting stent with a biodegradable polymer-based Biolimus A9 eluting stent and a bare metal stent in balloon denuded and radiated hypercholesterolemic rabbit iliac arteries. Catheter Cardiovasc Interv 2012;80:429-436.
Impact Factor 2.107
http://onlinelibrary.wiley.com/doi/10.1002/ccd.23407/pdf

11. **Tada, N., et al.** Polymer-free Biolimus A9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ Cardiovasc Interv 2010; 3:174-183. Impact Factor 5.316
http://circinterventions.ahajournals.org/content/3/2/174.full.pdf+html

Selected Conference Presentations [12-32]

12. **Richardt G.** Polymer-free DES in high bleeding risk patients with diabetes mellitus: a pre-specified substudy of the LEADERS FREE trial. PCR (2017)
https://www.pcronline.com/Cases-resources-images/Resources/Course-videos-slides/2017/Coronary-interventions-in-patients-with-diabetes-and-kidney-dysfunction

13. **Durand-Zaleski I.** Antiplatelet regime after PCI: an ongoing debate
Cost-effectiveness of polymer-free drug-coronary stents in patients at high bleeding risk: economic evalaution of the LEADERS FREE trial. PCR (2017)

14. **Iñiguez A.** Radial access: is everything feasible?
Impact of vascular access on outcome after PCI in patients at high bleeding risk - A pre-specified subanalysis of the LEADERS FREE trial. PCR (2017)

15. **Sardella G.** New DES and DES comparisons
G. Sardella Polymer-free biolimus-eluting stents in all-comer patients: the RUDI-Free registry. PCR (2017)
https://www.pcronline.com/Cases-resources-images/Resources/Course-videos-slides/2017/New-DES-and-DES-comparisons

16. **Morice M-C.** New DES and DES comparisons. Two-year follow-up of LEADERS FREE ACS. PCR (2017)
http://solaci.org/en/2017/05/30/leaders-free-acs-good-results-for-the-polymer-free-stent-at-2-years-in-acs/

Selected Conference Presentations [12-32]

17. **Werner G.** Late-breaking trials and trial updates. A randomised multicentre trial to evaluate the utilisation of revascularization or optimal medical therapy for the treatment of coronary CTO (EuroCTO). PCR (2017) *https://www.tctmd.com/news/eurocto-revascularization-bests-medical-therapy-quality-life-cto-lesions*

18. **Tzafriri R.** Sirolimus analog lipophilicity dictates release kinetics and tissue retention after implantation of polymer free drug coated stents. Poster presentation, EuroPCR (2017)

19. **Edelman. E** BA9 distribution modelling in vascular wall. EuroPCR (2017)

20. **Carrié D.** Biolimus A9 Coated vs Bare Metal Stents in Patients Requiring Oral Anticoagulation. A Prespecified Subgroup Analysis of the LEADERS FREE Trial. TCT (2016)

21. **Urban P.** LEADERS FREE: Two-Year Clinical and Subgroup Outcomes From a Prospective, Randomized Trial of a Polymer-Free Drug-Coated Stent and a Bare Metal Stent in Patients With Coronary Artery Disease at High Bleeding Risk. TCT (2016)

22. **Costa R.** Sequential Angiographic Analysis of the Novel Polymer-Free Biolimus-Coated Stents for the Treatment of Diseased Coronary Vessels. Poster presentation, TCT (2016)

23. **Morice M.C.** PCI for Elderly patients at High Bleeding Risk. A pre-specified substudy of the LEADERS FREE trial. ESC (2016)

24. **Naber C.K.** Biolimus A9 drug-coated stent vs. bare metal stent in patients presenting with ACS - a pre-specified LEADERS FREE ACS substudy. EuroPCR (2016)

25. **Urban P.** The balance of thrombosis and bleeding in patients at high-bleeding risk from LEADERS FREE. EuroPCR (2016)

26. **Urban P.** Biolimus-Coated vs. Bare-Metal Coronary Stents in High Bleeding Risk Patients. TCT (2015)

27. **Lee, W.L.S.** The first establishment of early healing profile and 9-month outcomes of a new polymer-free biolimus A9 drug-coated stent by longitudinal sequential OCT follow-ups: the EGO-BIOFREEDOM study. EuroPCR (2015)

28. **Kinnaird, T., et al** Early experience implanting a polymer-free biolimus A9 drug coated stent in patients treated with warfarin from two United Kingdom centers. Poster presentation, EuroPCR (2015)

29. **Kinnaird, T., et al** Early experience implanting a polymer-free biolimus A9 drug-coated stent in complex real- world patients from 2 United Kingdom centers. Poster presentation. EuroPCR (2015)

30. **Grube, E., et al.** Five year and final report of BioFreedom First-In-Man, a randomized trial comparing polymer-free BioFreedom™ stents with durable polymer Taxus Liberté™ stents. TCT (2014)

31. **Urban, P., et al.** Patients at high risk of bleeding, A forgotten population In DES trials? Insights from the on- going LEADERS FREE trial. TCT (2014)

32. **Urban, P.** LEADERS FREE - Double blind comparison of a polymer free active stent (BioFreedom) and the bare metal stent (Gazelle) in a population of patients at high risk of bleeding with only one month DAPT.

Last updated: February 2018

BIOSENSORS INTERNATIONAL™

www.biosensors.com

BIOSENSORS EUROPE SA
Rue de Lausanne 29 - 1110 Morges - Switzerland
Tel.: +41 (0)21 804 80 00- Fax: +41 (0)21 804 80 01

BIOSENSORS INTERVENTIONAL TECHNOLOGIES PTE LTD
36 Jalan Tukang - Singapore 619266
Tel. +65 6213 5777 - Fax: +65 6213 5737

EN_40650_2018-d1